Professor of Surgery, UCSF
General Surgery
Dr. David M. Jablons, MD
|
|
Give Review
Dr. David M. Jablons practices General Surgery. He graduated from Albany Medical College. He has 5 awards "America's Top Doctors", "America's Top Doctors for Cancer", "Fellow (FACS)", "Super Doctor" and "Top MD". David Jablons is a published MD. He has 101 publications published. The most current publication "SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer." Doctor David M. Jablons, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.
- Operative and Perioperative Pulmonary Emboli.
- Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
- Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
- Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
- An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
- The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
- Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease.
- Lung Tumorigenesis in a Conditional Cul4A Transgenic Mouse Model.
- A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.
- Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
- Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.
- Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.
- Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.
- Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
- Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
- Targeting Gli transcription activation by small molecule suppresses tumor growth.
- Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.
- Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.
- Gli as a novel therapeutic target in malignant pleural mesothelioma.
- Divergent Management Strategies for Typical Versus Atypical Carcinoid Tumors of the Thoracic Cavity.
- SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.
- The role of stem cells in airway repair: implications for the origins of lung cancer.
- A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
- Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells.
- A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease.
- Inhibition of CK2α Down-Regulates Hedgehog/Gli Signaling Leading to a Reduction of a Stem-Like Side Population in Human Lung Cancer Cells.
- Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
- One size does not fit all lung cancer patients.
- Implications of Delayed Initiation of Radiotherapy: Accelerated Repopulation after Induction Chemotherapy for Stage III Non-small Cell Lung Cancer.
- Transgenic mice for cre-inducible overexpression of the Cul4A gene.
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
- Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
- Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.
- Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
- Volume CT for diagnosis of nodules found in lung-cancer screening.
- Cul4A is an oncogene in malignant pleural mesothelioma.
- Genomic prognostic models in early-stage lung cancer.
- A multi-marker assay to distinguish malignant melanomas from benign nevi.
- Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity.
- mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
- Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
- A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
- Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.
- Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription.
- Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
- Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells.
- Diagnosis and treatment of bronchioloalveolar carcinoma.
- Natural history of stage I non-small cell lung cancer: implications for early detection.
- EGFR expression and mutational analysis as a predictive test.
- Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical...
- Update on the molecular biology of malignant mesothelioma.
- Five-gene signature in non-small-cell lung cancer.
- Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.
- Clinical characteristics and survival of patients with surgically resected, incidentally detected lung cancer.
- An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.
- Patterns of metastasis in human solid cancers.
- Novel therapies targeting signaling pathways in lung cancer.
- Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
- Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer.
- Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
- Current concepts in bronchioloalveolar carcinoma biology.
- Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database.
- Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
- Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
- Bronchioloalveolar carcinoma: a review.
- A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
- Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
- Wnt signaling in stem cells and non-small-cell lung cancer.
- Unusual thoracic problems in patients with malignancies: case 3. Carcinoid tumor of the thymus.
- Changes in radiographic abnormalities in organ donors: associations with lung transplantation.
- Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
- Salmonella infection in an anterior mediastinal mass.
- Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma.
- Cloning and characterization of the promoter of human Wnt inhibitory factor-1.
- Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
- An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
- Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
- Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metas...
- Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.
- Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
- Isolated pulmonary arteriovenous malformations requiring anatomic resection.
- Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
- A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
- Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer.
- Future directions: oncolytic viruses.
- SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
- Potential of mobile intraoperative radiotherapy technology.
- Intraoperative radiation therapy in the multimodality approach to upper aerodigestive tract cancer.
- Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
- c-Kit is not expressed in malignant mesothelioma.
- Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2.
- Cloning and characterization of a functional promoter of the human SOCS-3 gene.
- Matrix metalloproteinase expression in lung cancer.
- Emergent surgery for massive pulmonary embolism on the basis of clinical diagnosis.
- Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
- Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
- Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
- SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
- Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
Schools
Albany Medical College
National Naval Mc
New Eng Mc Tufts University
National Cancer Institute Nih
Ny Hospital Cornell University
Procedures Preformed
- Chest CT (incl. Heart and Lungs)
- Decortication and Pleurectomy
- Esophagectomy (Esophagogastrostomy, Esophagojejunostomy)
- Excision of Tracheal Tumor or Stenosis
- View All
Doctors Specialties
- Cardiac Surgery
- Thoracic Oncology
- General Surgery
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FACS)
- Super Doctor
- Top MD
Education
-
New York Presbyterian Hospital - Cornell Campus -
Tufts Medical Center -
Albany Medical College
Hospital
-
San Francisco General Hospital and Trauma Center -
Sequoia Hospital -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1346206190 | |
| NPPES Provider LastName | JABLONS | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 941430001 | |
| NPPES Provider State | CA | |
| Specialty Description | Thoracic Surgery | |
| Total Claim Count | 138.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 50.0 | |
| Percent Opioid Claims | 36.23 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346206190 |
| Last Name Of The Provider | JABLONS |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Jasleen Kukreja, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack D. Ghatan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tom R. Karl, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Beverly L. Bolinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roberto D. Mendez, MD |
|
|
Dr. Matthew J. Callaghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ginger Xu, MD
This Doctor is OpenDoctor Recommended.
|